BetterLife Pharma Inc. Announces Closing of US$100 Million Public Offering of Common Shares and Pre-Funded Warrants
BetterLife Pharma Inc. Announces Filing of Final Prospectus for US$100 Million Public Offering of Common Shares and Pre-Funded Warrants
BetterLife Pharma Inc. Announces Pricing of US$100 Million Public Offering of Common Shares and Pre-Funded Warrants
pharmaceutical investing BetterLife To Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
pharmaceutical investing BetterLife's Non-hallucinogenic LSD For Treating Mood Disorders Highlighted in Drug Discovery & Development Article
pharmaceutical investing Promise of BetterLife's Non-hallucinogenic LSD For Treating Mood Disorders Highlighted in Medical Xpress Article
pharmaceutical investing BetterLife Files Amended and Restated Offering Document for Offering of Units
pharmaceutical investing Omineca Announces Upsized and Fully Allocated $2.8 Million Brokered Financing of Flow-Through Units
pharmaceutical investing Betterlife Publishes Promising Results from a Study Titled "A Non-Hallucinogenic LSD Analog With Therapeutic Potential For Mood Disorders"
QIMC Identifies Three Fault-Controlled Helium Zones at New Salem-Apple River, Nova Scotia, and Expands Seismic Program to Approximately 50 Line-Kilometres
Flow Metals Identifies Widespread Epithermal Alteration and District-scale Structural Controls at Sixtymile
